Back

Sortilin inhibition treats multiple neurodegenerative lysosomal storage disorders.

Leppert, H. G.; Anderson, J. T.; Timm, K. J.; Davoli, C.; Pratt, M. A.; Booth, C. D.; White, K. A.; Rechtzigel, M.; Meyerink, B. L.; Johnson, T. B.; Brudvig, J. B.; Weimer, J. M.

2023-09-22 neuroscience
10.1101/2023.09.22.559064 bioRxiv
Show abstract

Lysosomal storage disorders (LSDs) are a genetically and clinically diverse group of diseases characterized by lysosomal dysfunction. Batten disease is a family of severe LSDs primarily impacting the central nervous system. Here we show that AF38469, a small molecule inhibitor of sortilin, improves lysosomal and glial pathology across multiple LSD models. Live-cell imaging and comparative transcriptomics demonstrates that the transcription factor EB (TFEB), an upstream regulator of lysosomal biogenesis, is activated upon treatment with AF38469. Utilizing CLN2 and CLN3 Batten disease mouse models, we performed a short-term efficacy study and show that treatment with AF38469 prevents the accumulation of lysosomal storage material and the development of neuroinflammation, key disease associated pathologies. Tremor phenotypes, an early behavioral phenotype in the CLN2 disease model, were also completely rescued. These findings reveal sortilin inhibition as a novel and highly efficacious therapeutic modality for the treatment of multiple forms of Batten disease.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Brain
◐ 168 papers in training set
Top 0.2%
13.2%
Similar papers in this journal
2
Neurobiology of Disease
○ 148 papers in training set
Top 0.1%
13.2%
Similar papers in this journal
3
Nature Communications
○ 5641 papers in training set
Top 28%
5.3%
Similar papers in this journal
4
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 10%
4.9%
Similar papers in this journal
5
JCI Insight
● 277 papers in training set
Top 1%
4.9%
Similar papers in this journal
6
Molecular Neurodegeneration
○ 55 papers in training set
Top 0.5%
4.1%
7
Journal of Clinical Investigation
● 179 papers in training set
Top 1%
3.3%
8
Cell Reports
○ 1498 papers in training set
Top 11%
3.3%
50% of probability mass above
9
eLife
● 5828 papers in training set
Top 34%
3.3%
10
npj Parkinson's Disease
○ 105 papers in training set
Top 0.6%
2.8%
11
Autophagy
○ 39 papers in training set
Top 0.2%
2.2%
12
eBioMedicine
○ 183 papers in training set
Top 2%
2.2%
13
Brain Communications
◐ 166 papers in training set
Top 2%
2.2%
14
Neuron
○ 337 papers in training set
Top 3%
1.8%
15
Science Advances
● 1243 papers in training set
Top 19%
1.8%
16
Movement Disorders
○ 71 papers in training set
Top 0.5%
1.7%
17
Cell Reports Medicine
○ 153 papers in training set
Top 2%
1.7%
18
The American Journal of Human Genetics
○ 234 papers in training set
Top 2%
1.5%
19
Annals of Neurology
○ 64 papers in training set
Top 1%
1.2%
20
iScience
○ 1154 papers in training set
Top 25%
1.2%
21
Scientific Reports
○ 3612 papers in training set
Top 62%
1.2%
22
Communications Medicine
○ 113 papers in training set
Top 2%
1.2%
23
Communications Biology
○ 993 papers in training set
Top 20%
1.2%
24
Journal of Neuroinflammation
○ 61 papers in training set
Top 1%
1.1%
25
Molecular Psychiatry
○ 282 papers in training set
Top 5%
1.1%
26
Cell
○ 431 papers in training set
Top 9%
0.9%
27
Alzheimer's & Dementia
177 papers in training set
Top 2%
0.9%
28
Acta Neuropathologica
○ 58 papers in training set
Top 1%
0.6%
29
Acta Neuropathologica Communications
○ 89 papers in training set
Top 2%
0.6%
30
Stem Cell Reports
○ 130 papers in training set
Top 2%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.